Trial Profile
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Cemiplimab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 06 Mar 2024 According to Invio Therapeutics media release, through 2023, patients involved in the trial continued to receive drug. In the first half of 2024, INOVIO expects to finalize next steps for further development of INO-5401 in conjunction with Regeneron and investigators.
- 08 Nov 2022 According to Invio Therapeutics media release, the company anticipates the data announcements in the coming months.
- 07 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.